Management of Catamenial Epilepsy in Women of Reproductive Age
For women with catamenial epilepsy and regular menses, optimize existing antiepileptic drugs first; if seizures remain uncontrolled, consider intermittent cyclic treatments during vulnerable menstrual phases, though evidence for hormonal therapy remains limited. 1
Initial Management Approach
Step 1: Optimize Baseline Antiepileptic Drug Therapy
- Review current antiepileptic drug (AED) regimen to ensure it is appropriate for the specific seizure type 1
- Verify the patient is on adequate doses before adding hormonal interventions
- This is the recommended first-line approach, as evidence for hormonal treatments is insufficient 2
Step 2: Identify the Catamenial Pattern
Document seizure patterns relative to menstrual cycle for at least 3 months to identify one of three patterns 3, 2:
- C1 (Perimenstrual): Seizure exacerbation from day -3 to +3 around menstruation
- C2 (Periovulatory): Seizure increase around ovulation (days 10-14)
- C3 (Luteal): Seizure worsening during inadequate luteal phase (days 10-28)
Step 3: Consider Medication-Related Endocrine Effects
Pay particular attention to valproate use, as it is associated with significant reproductive endocrine dysfunction 1:
- 45% of women on valproate monotherapy develop menstrual irregularities
- 60% develop polycystic ovaries
- 30% have elevated testosterone
- Consider switching from valproate if reproductive endocrine disorders are present, though balance this against seizure control risk 1
Enzyme-inducing AEDs (carbamazepine, phenobarbital, phenytoin) reduce biologically active sex hormones through increased SHBG production 1
Intermittent Cyclic Treatment Options (For Regular Menses)
Natural Progesterone
- Dosing: 600 mg/day during luteal phase (days 14-28) 3
- Evidence: One large RCT showed benefit specifically for C1 (perimenstrual) pattern, but not for C2 or C3 patterns 4, 3
- Generally well tolerated 4
- Limitation: Conflicting evidence from controlled trials; effectiveness may depend on allopregnanolone levels 5
Alternative Intermittent Treatments
When progesterone is ineffective or not tolerated:
- Benzodiazepines (e.g., clobazam) during vulnerable days 4
- Acetazolamide during vulnerable days 4, 3
- Increase dose of existing AED during vulnerable menstrual phases 3
Treatment for Irregular Menses or Refractory Cases
When intermittent treatments fail, consider pharmacologic amenorrhea 3:
- Medroxyprogesterone (Depo-Provera): Induces amenorrhea, shown to reduce catamenial seizures 6, 3
- Sustained oral contraceptives: Continuous use without placebo week 6, 3
- GnRH analogues (triptorelin, goserelin): For complete menstrual suppression 4
Critical Monitoring Requirements
Regular Assessment at Each Visit 1
- Menstrual cycle regularity
- Weight changes (valproate, carbamazepine, vigabatrin, gabapentin cause weight gain) 1
- Signs of hyperandrogenism: hirsutism, acne
- Galactorrhea (suggests hyperprolactinemia)
- Fertility concerns
Laboratory Evaluation When Indicated 1
- Hormonal measurements: testosterone, LH, FSH, prolactin
- Pelvic ultrasonography if clinical features suggest PCOS
- Progesterone levels to assess luteal phase adequacy
Important Clinical Pitfalls
Valproate in reproductive-age women: Associated with PCOS development (64% in some studies), weight gain, and hyperandrogenism 1. Discontinuation can reverse these effects 1.
Drug interactions: AEDs can reduce contraceptive efficacy and vice versa 6. Enzyme-inducing AEDs require higher contraceptive doses.
Temporal lobe epilepsy: 12% develop hypothalamic amenorrhea (vs. 1.5% in general population) 1. Left-sided temporolimbic epilepsy associated with PCOS; right-sided with hypothalamic amenorrhea 1.
Evidence limitations: Despite widespread use, randomized controlled trials show no significant benefit for norethisterone 4, and progesterone evidence is conflicting 4, 5. Uncontrolled studies suggest benefit, but controlled trials do not consistently demonstrate efficacy.
Quality of Life Considerations
- Anovulatory cycles from reproductive endocrine disorders may worsen seizure frequency 1
- PCOS associated with increased migraine, mood disorders, and female malignancies 1
- Early menopause occurs more frequently (4% vs. 1% in general population) 1
- Infertility rates are elevated in women with epilepsy, partly due to endocrine dysfunction 1
The balance between seizure control and medication-related endocrine side effects must be carefully weighed, as switching medications carries seizure relapse risk 1.